NCT01381705 is a clinical trial of rituximab in Lymphoma, sponsored by ECOG-ACRIN Cancer Research Group.

Who is sponsoring NCT01381705?

NCT01381705 is sponsored by ECOG-ACRIN Cancer Research Group.

What drugs are being tested in NCT01381705?

Interventions in NCT01381705: rituximab, DNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review.

Is NCT01381705 still recruiting?

NCT01381705 is currently completed. Last updated 17 May 2017.

Last reviewed 2017-05-17 · How we verify

NCT01381705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Completed Last updated 17 May 2017

What this trial tests

trial testing rituximab in Lymphoma in 259 participants. Completed in 6 July 2012.

Timeline

6 February 2012

Primary endpoint
6 July 2012

6 July 2012

Quick facts

Lead sponsor	ECOG-ACRIN Cancer Research Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	259
Start date	6 February 2012
Primary completion	6 July 2012
Estimated completion	6 July 2012

Drugs / interventions tested

rituximab — full drug profile →
DNA analysis
gene expression analysis
polymorphism analysis
laboratory biomarker analysis — full drug profile →
medical chart review

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

ECOG-ACRIN Cancer Research Group

Who can join

Adults 18 to 120, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.
Zhang X, Yang Z, Yan S, Zhan M, et al · · 2025 · PMID 41071909 · DOI 10.1177/15330338251383634

Verify or expand the search:

Other trials of rituximab

Trials testing the same drug.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07073833 — The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma · Phase 1 · recruiting
NCT06700798 — Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial · Phase 2 · recruiting
NCT06655896 — Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis · Phase 2 · recruiting
NCT07041268 — Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab · Phase 2 · recruiting

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other ECOG-ACRIN Cancer Research Group trials

Trials by the same sponsor.

NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting
NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting
NCT06084845 — Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for P · Phase 2 · withdrawn
NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01381705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group
Last refreshed: 17 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01381705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing